Regulatory Affairs 3PO

FDA Third Party Review Unit dedicated to supporting medical device manufacturers

Our Regulatory Services

Comprehensive regulatory affairs services designed to navigate the complex FDA landscape and accelerate your product development timeline.

FDA 510(k) Third Party Review

Expert 510(k) reviews for Class I and eligible Class II medical devices through our FDA 3P510k pathway alignment

Medical Device Regulatory Strategy

Comprehensive regulatory strategy development for medical device manufacturers targeting U.S. market access

Quality Management Systems

Quality management systems aligned with FDA and ISO 13485 standards with rigorous compliance processes

Regulatory Compliance Reviews

Independent and expert evaluations of medical device submissions with transparent review processes

Data Security & Confidentiality

Advanced encryption technologies and secure digital platforms to protect sensitive client data

Global Market Access

Expertise in FDA processes with understanding of Indian and regional manufacturing landscapes

Our FDA Third Party Review (3PO) Team

Our FDA Third Party Review (3PO) Team comprises highly experienced regulatory professionals dedicated to delivering thorough, independent, and expert evaluations of medical device 510(k) submissions. We combine deep regulatory knowledge, practical clinical research experience, and rigorous quality management to ensure a compliant, efficient, and transparent review process.

Advantages of Partnering with an Indian FDA 3PO Organization

Cost-Effective Services: India's competitive cost environment enables top-tier regulatory reviews at significantly reduced fees

Time Zone and Cultural Alignment: Timely communication and collaboration with Asia-Pacific manufacturers

In-Depth Local Knowledge: Nuanced understanding of Indian and regional manufacturing landscapes

First-Mover Advantage: One of the earliest India-based FDA-accredited 3POs with unique market position

Scalable Expertise: Broad network of experts and consultants for efficient scaling without compromising quality

Advanced Technology: Streamlined workflows with automation to enhance review accuracy and reduce turnaround times

Our Expert Team

Led by seasoned regulatory professionals with extensive FDA experience and deep understanding of the Third Party Review Unit processes.

Rakshith Katta

Director – Regulatory Affairs

Experience: 12+ years

Over 12 years of global regulatory experience, including 8+ years consulting directly with the FDA in Washington, DC. MBA from Johns Hopkins University and Master's degree in Regulatory Affairs for Drugs, Biologics, and Medical Devices from Northeastern University.

Dr. Suresh Anand

Lead Reviewer

Experience: 20+ years

PhD from IIT Madras, specialized in biomedical optical spectroscopy and vascular dynamics. Over 20 years of expertise in medical device regulatory affairs, FDA 510(k) submissions, EU Technical Files, and global regulatory compliance.

Nancy Pavan

Lead Quality Assurance Consultant

Experience: 15+ years

Specializes in quality management systems aligned with FDA and ISO 13485 standards. Leads internal audits, manages CAPA processes, and coordinates SOP development and annex template creation.

Commitment to Data Safety and Process Efficiency

Data Security

SMO India is committed to maintaining the highest levels of data security and confidentiality. We utilize advanced encryption technologies and secure digital platforms to protect sensitive client data and submission materials.

Process Efficiency

Our streamlined workflows, supported by automation and technology, enhance review accuracy, reduce turnaround times, and ensure strict adherence to FDA regulatory requirements.

Contact Our Regulatory Affairs Team

Ready to accelerate your regulatory pathway? Contact our team of experts to discuss your specific needs and learn how our FDA 3PO partnership can benefit your project.

Contact Information

Rakshithkatta@smo-india.com
+91 9148779836

Important Note

Note: SMO India is in the process of seeking FDA Third Party Reviewer accreditation. No service is offered as accredited until FDA approval is granted.